$QGEN

Qiagen (QGEN) shares rose over 10% after reports of potential takeover interest from private equity firms, including EQT, Advent, and KKR, with offers around $50 per share. This exceeds the stock's $44.46 analyst consensus price target. The company is working with Moelis & Co. and Goldman Sachs on strategic options. QGEN develops molecular testing technologies and has seen increased retail investor bullish sentiment.

Qiagen (QGEN) launched QIAsymphony Connect, an automated clinical nucleic acid extraction platform approved by the FDA and EUDAMED. The system aims to streamline workflows in molecular diagnostics, targeting growth areas like oncology and infectious disease testing. Qiagen, with a $9.0 billion market cap, expects the platform to drive adoption and consumables demand. Investors will watch for future disclosures on its impact on installed base growth and revenue.

QIAGEN N.V. reported a voting rights notification from the AFM on August 28, 2026, detailing transactions by Bank of America Corporation. The notification includes various types of shares and options, with total holdings representing 4.69% of capital and voting rights, both directly and indirectly.

10x Genomics won a $4.8 million award in a patent case against a Qiagen unit. The ruling may impact both companies' financials and legal strategies.

QIAGEN N.V. (NYSE: QGEN) launched QIAsymphony Connect, an automated clinical nucleic acid extraction platform. The IVD-compliant system builds on the established QIAsymphony platform, with over 3,300 placements, and supports high-growth applications like liquid biopsy. The company reported initial customer orders and completed regulatory listings in the U.S. and Europe.

QIAGEN launched QIAsymphony Connect, a new lab system that processes up to 96 samples in four batches, improving productivity and sample traceability. The platform supports high-growth applications like liquid biopsy and is compatible with existing QIAsymphony kits. QIAGEN has received initial customer orders, reflecting early market adoption. The company expects the platform to enhance clinical molecular testing workflows and strengthen its Sample to Insight portfolio.

Qiagen N.V. reported a voting rights notification from the AFM on August 25, 2026. Goldman Sachs Group Inc. holds various types of shares and financial instruments, totaling 3.27% capital interest and 3.05% voting rights in Qiagen. The notification details indirect holdings and potential voting rights.

Morgan Stanley ranked EU diagnostics stocks by China reform risk, estimating FY27 EBIT impacts: bioMérieux (5%), DiaSorin (2%), Siemens Healthineers (1%), and Qiagen (1%). China's lab-fee reform may cause 15% net price compression, with varying exposure across companies.

QIAGEN N.V. (QGEN) shares fell 3.3% after announcing Jonathan M. Pratt as CEO, replacing Thierry Bernard. The company's strategic review continues, and Q3/2026 outlook was reaffirmed. Investors may see leadership change as uncertainty.

Qiagen N.V. (QGEN) named Jonathan M. Pratt as CEO, effective September 1, 2026. Pratt has 25 years of experience in life sciences and will succeed Thierry Bernard. The company is in takeover talks with firms like EQT AB and KKR & Co., according to Bloomberg. Qiagen reaffirmed its 2026 outlook.